Transcriptomic analysis further confirms Neo-BCV’s unique ability to modulate the immune microenvironment by specifically inhibiting the JAK2-STAT3 signaling pathway, a key mechanism associated with innate and adaptive immune responses that has not been extensively explored in previous DCs-based cancer immunotherapy studies (Figure 7). This evidence concerns the gene JAK2 and cancer.